Project BioShield funding for Ebola countermeasures

Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.

This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.

The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.

Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.
This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.
The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.

Our Current Sponsors

  • 908 Devices
  • Airboss
  • Argon
  • Avon
  • Battelle
  • Biofire Idaho
  • Bruker
  • Bw Tek
  • Cap Force 1 Decon 01
  • CQC
  • Cristanini
  • Decon Seven Systems
  • DQE
  • Dxterity
  • Emergent Biosol
  • Endeavor Roborics
  • Ecotest
  • Federal Resources
  • First Line Technology
  • Flir
  • Futurtech
  • Hameln
  • Metrohm Raman
  • NBC sys
  • Proengin
  • Qinetiq
  • RSDecon
  • Tex Shield
  • Wl Gore